Lapalu S, Moisand C, Mazarguil H, Cambois G, Mollereau C, Meunier J C
Unité de Neuropharmacologie Moléculaire, Institut de Pharmacologie et de Biologie Structurale, Centre National de la Recherche Scientifique, Toulouse, France.
FEBS Lett. 1997 Nov 17;417(3):333-6. doi: 10.1016/s0014-5793(97)01318-5.
The aim of the present study was to delineate the functional domains of nociceptin (noc), a neuropeptide which is structurally related to dynorphin A (dyn). The binding and biological potencies towards the nociceptin (ORL1) and dynorphin A (kappa-opioid) receptors of twenty dyn/noc and noc/dyn hybrid peptides were compared with those of the parent heptadecapeptides. Replacement of as many as eleven residues in the C-terminus of dynorphin by the corresponding nociceptin sequence has no significant effect on binding and biological activity towards the kappa-opioid receptor. In marked contrast, replacement of as few as six residues (RKLANQ) in the C-terminus of nociceptin by the corresponding dynorphin sequence (LKWDNQ) dramatically impairs both affinity and activity towards the ORL1 receptor. This clearly indicates that the two neuropeptides have different functional architectures, despite the dual structural homology of both ligands and receptors. Moreover, the recombinant peptide approach led us to identify hybrids whose sequences differ only at positions 5 and 6 and displaying opposite or no receptor selectivity. One contains the dynorphin Leu5-Arg6 sequence and prefers the kappa-opioid receptor, whereas the other comprises the nociceptin Thr5-Gly6 sequence and prefers the ORL1 receptor. A third, containing the mixed dynorphin/nociceptin Leu5-Gly6 sequence, does not discriminate between the two types of receptor.
本研究的目的是描绘痛敏肽(noc)的功能域,痛敏肽是一种与强啡肽A(dyn)在结构上相关的神经肽。将20种强啡肽/痛敏肽和痛敏肽/强啡肽杂合肽对痛敏肽(ORL1)受体和强啡肽A(κ-阿片样物质)受体的结合力及生物学活性,与亲本十七肽进行了比较。用相应的痛敏肽序列替换强啡肽C末端多达11个残基,对其与κ-阿片样物质受体的结合及生物学活性无显著影响。与之形成鲜明对比的是,用相应的强啡肽序列(LKWDNQ)替换痛敏肽C末端少至6个残基(RKLANQ),会显著损害其对ORL1受体的亲和力和活性。这清楚地表明,尽管两种配体和受体都存在双重结构同源性,但这两种神经肽具有不同的功能结构。此外,重组肽方法使我们鉴定出一些杂合肽,它们的序列仅在第5和第6位不同,且表现出相反或无受体选择性。一种含有强啡肽Leu5-Arg6序列,偏好κ-阿片样物质受体,而另一种含有痛敏肽Thr5-Gly6序列,偏好ORL1受体。第三种含有混合的强啡肽/痛敏肽Leu5-Gly6序列,对两种受体无区分性。